Results 1 to 10 of about 25,648 (169)
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Experimental Hematology & Oncology, 2022 Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial apoptotic pathway.
Yilan Xu, Haige Ye
doaj +1 more source
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
Clinical and Translational Science, 2020 Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetoclax on ...
Ali A. Alhadab +2 more
doaj +1 more source
Haematologica, 2020 Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance ...
Xinyu Li +17 more
doaj +1 more source
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
Pharmaceutics, 2022 Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug
Eric D. Eisenmann +9 more
doaj +1 more source
Cell Death and Disease, 2022 Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity.
Damjan Avsec +6 more
doaj +1 more source
On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
Pharmaceutics, 2020 Venetoclax is an orally bioavailable, B-cell lymphoma-2 (BCL-2) selective inhibitor, used for the treatment of various types of blood cancers, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Nina Žigart +3 more
doaj +1 more source
Targeting BCL-2 regulated apoptosis in cancer [PDF]
, 2018 The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death ...
Campbell, Kirsteen J. +1 more
core +1 more source
Cancer Medicine, 2023 Background Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML.
Louise Laloi +29 more
doaj +1 more source
Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]
, 2017 We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core +1 more source
Scientific Reports, 2023 Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials ...
Lilly Velentza +5 more
doaj +1 more source